Article

Circulating antibodies to carcinoembryonic antigen related to improved recurrence-free survival of patients with colorectal carcinoma.

Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Cancer Centre, Sun Yat-sen University, Guangzhou, China.
The Journal of international medical research (impact factor: 0.9). 01/2011; 39(3):838-45. pp.838-45
Source: PubMed

ABSTRACT This prospective study evaluated the prognostic value of antibodies to carcinoembryonic antigen (anti-CEA), detected by indirect immunosorbent assay, in the serum of colorectal carcinoma patients. Serum carcinoembryonic antigen (CEA) concentrations, measured by electrochemiluminescence immunoassay, were elevated in 26 (37.7%) of 69 patients with colorectal cancer and could not be detected among the 28 patients with benign intestinal conditions or 37 healthy individuals who comprised the control groups. Anti-CEA immuno globulin (Ig)G or IgM was detected by immunonephelometry in 44 (63.8%) patients with colorectal cancer, three (10.7%) with benign intestinal conditions and four (10.8%) healthy blood donors. Differences in antibody detection frequencies between the cancer patient group and the control groups were statistically significant. Titres of anti-CEA correlated significantly with CEA levels and Dukes' cancer stage. Antibody titre was an independent, significant, favourable predictor for 5-year recurrence-free survival. It is concluded that measurement of serum anti-CEA combined with CEA might be useful as a tumour marker and to assess prognosis. These results need to be confirmed in large, well-controlled, randomized clinical trials.

0 0
 · 
0 Bookmarks
 · 
19 Views
  • Source
    Article: The secret ally: immunostimulation by anticancer drugs.
    Lorenzo Galluzzi, Laura Senovilla, Laurence Zitvogel, Guido Kroemer
    [show abstract] [hide abstract]
    ABSTRACT: It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents--including classical chemotherapeutics and targeted compounds--stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.
    dressNature Reviews Drug Discovery 01/2012; 11(3):215-33. · 29.01 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

37 healthy individuals
 
5-year recurrence-free survival
 
69 patients
 
anti-CEA correlated
 
Anti-CEA immuno globulin
 
antibody detection frequencies
 
Antibody titre
 
benign intestinal conditions
 
CEA levels
 
colorectal cancer
 
colorectal carcinoma patients
 
control groups
 
Dukes' cancer stage
 
electrochemiluminescence immunoassay
 
favourable predictor
 
indirect immunosorbent assay
 
prognostic value
 
serum anti-CEA
 
tumour marker
 
well-controlled